A detailed history of Columbia Asset Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Columbia Asset Management holds 40,537 shares of ABBV stock, worth $8.13 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares
40,537
Previous 40,365 0.43%
Holding current value
$8.13 Million
Previous $6.26 Million 11.16%
% of portfolio
1.3%
Previous 1.27%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$154.79 - $180.76 $26,623 - $31,090
172 Added 0.43%
40,537 $6.95 Million
Q4 2023

Feb 09, 2024

SELL
$137.6 - $154.97 $9,769 - $11,002
-71 Reduced 0.18%
40,365 $6.26 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $48,893 - $56,601
-366 Reduced 0.9%
40,436 $6.03 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $726,684 - $904,311
-5,484 Reduced 11.85%
40,802 $5.5 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $124,943 - $143,890
-864 Reduced 1.83%
46,286 $7.38 Million
Q4 2022

Feb 10, 2023

SELL
$138.31 - $165.87 $36,652 - $43,955
-265 Reduced 0.56%
47,150 $7.62 Million
Q3 2022

Nov 03, 2022

SELL
$134.21 - $153.93 $166,823 - $191,334
-1,243 Reduced 2.55%
47,415 $6.36 Million
Q2 2022

Aug 26, 2022

SELL
$137.62 - $174.96 $957,147 - $1.22 Million
-6,955 Reduced 12.51%
48,658 $7.45 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $47,806 - $60,488
445 Added 0.81%
55,613 $7.53 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $83,098 - $94,329
781 Added 1.44%
55,168 $5.95 Million
Q2 2021

Aug 02, 2021

SELL
$105.21 - $117.21 $814,325 - $907,205
-7,740 Reduced 12.46%
54,387 $6.13 Million
Q1 2021

May 28, 2021

BUY
$102.3 - $112.62 $600,194 - $660,741
5,867 Added 10.43%
62,127 $6.72 Million
Q4 2020

Feb 11, 2021

BUY
$80.49 - $108.67 $92,965 - $125,513
1,155 Added 2.1%
56,260 $6.03 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $96,992 - $113,837
-1,129 Reduced 2.01%
55,105 $4.83 Million
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $3.28 Million - $4.38 Million
-44,655 Reduced 44.26%
56,234 $5.52 Million
Q1 2020

May 14, 2020

BUY
$64.5 - $97.79 $3.32 Million - $5.03 Million
51,440 Added 104.03%
100,889 $47.7 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $173,256 - $216,780
2,402 Added 5.11%
49,449 $43.8 Million
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $216,651 - $260,476
3,440 Added 7.89%
47,047 $3.56 Million
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $472,448 - $603,900
7,191 Added 19.75%
43,607 $3.17 Million
Q1 2019

May 20, 2019

BUY
$77.14 - $90.79 $139,391 - $164,057
1,807 Added 5.22%
36,416 $2.94 Million
Q4 2018

Feb 12, 2019

BUY
$77.85 - $96.01 $106,265 - $131,053
1,365 Added 4.11%
34,609 $3.19 Million
Q3 2018

Nov 06, 2018

BUY
$88.91 - $98.84 $50,767 - $56,437
571 Added 1.75%
33,244 $3.14 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $267,813 - $316,884
2,983 Added 10.05%
32,673 $3.03 Million
Q1 2018

May 07, 2018

SELL
$92.01 - $123.21 $18,862 - $25,258
-205 Reduced 0.69%
29,690 $2.81 Million
Q4 2017

Feb 05, 2018

SELL
$89.56 - $98.21 $47,019 - $51,560
-525 Reduced 1.73%
29,895 $2.89 Million
Q3 2017

Nov 07, 2017

BUY
$69.85 - $89.22 $2.12 Million - $2.71 Million
30,420
30,420 $2.7 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $354B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Columbia Asset Management Portfolio

Follow Columbia Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Columbia Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Columbia Asset Management with notifications on news.